Research Blogs

I had the privilege of attending the 2023 World Conference on Lung Cancer (WCLC) in Singapore with my colleague Dr. Bellinda King-Kallimanis. WCLC, the world's largest meeting

Currently, lung cancer screening using low-density computed tomography (LDCT) scans is available as a tool to screen for lung cancer in individuals at high risk of developing the

Recently, members of LUNGevity Foundation joined thousands of attendees from the US and around the world, including oncologists, scientists, biotech and pharmaceutical

Since 2016, the medical community has seen strong data showing that remote patient monitoring (RPM), which gives people living with cancer simple ways to report treatment side

Since 2020, LUNGevity has been engaged in research to understand the experiences of lung cancer patients, particularly those receiving care at community hospitals and those from

As Chief Investigator of the groundbreaking Cancer Research UK (CRUK) TRACERx study, you could say that Dr. Charles Swanton is having a moment. Launched nine years ago, TRACERx

Our lung tissue is made of different kinds of cells, including neuroendocrine cells. If these cells develop changes in their genome, they can begin to grow out of control and

The first week of April definitely started with a bang! After the 2019 in-person small cell lung cancer (SCLC) meeting—convened by the International Association for the Study of

Cancer Grand Challenges is a partnership between Cancer Research UK (CRUK) and the National Cancer Institute (NCI), which funds global teams of leading researchers across various

Each year, there is one key conference dedicated to bringing stakeholders together with the sole goal of discussing the development of treatments for thoracic cancer — the Targeted Therapies of Lung Cancer Meeting.

Tumors that have the ALK protein fused with another cancer-driving protein, such as the EML4 protein, are often referred to as ALK-positive tumors. Approximately 5% of advanced-stage adenocarcinoma, a type of NSCLC, will test positive for an ALK-fusion biomarker. Treating patients with ALK-positive lung cancer with a class of drugs called tyrosine kinase inhibitors (TKIs) has been an effective approach. However, as seen in other types of lung cancers treated with TKIs, eventually the tumors develop resistance to treatment and the tumor begins to grow again.

While our bodies can have a wide range of naturally occurring, harmless mutations in different genes, some mutations, called driver mutations, are key to driving the development of cancer. In the early 2000s, EGFR was the first gene in non-small cell lung cancer (NSCLC) to be matched with a targeted therapy.